12:00 AM
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bimagrumab: Phase II/III started

Novartis began a double-blind, placebo-controlled Phase II/III trial to evaluate 3 dose levels of IV bimagrumab in about 240 patients. MorphoSys said the start triggered an undisclosed milestone payment from Novartis under a 2007 deal granting the pharma exclusive...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >